Rx Imports Will Resolve Shortage Of Injectable Nutrition Drugs After Congressional Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Fresenius Kabi USA’s Norway plant is to supply the US with three injectable drugs used in total parenteral nutrition, primarily for treatment of premature infants; FDA has previously permitted importation of 11 other drugs that have been subject to shortages.
You may also be interested in...
Doxil Shortage Solution: FDA Chooses Middle Ground, Allows Import Of Unapproved Version
FDA is allowing Sun Pharma Global FZE to import its unapproved liposomal version of doxorubicin, Lipodox, to alleviate a shortage, but has not yet given the drug full approval.
Operation Warp Speed For Rare Diseases? US FDA Is Considering Pilot Programs
CBER director Peter Marks says the FDA may evaluate giving gene therapy products the ‘degree of responsiveness’ that COVID-19 vaccines received. In a discussion of the pandemic's effects on staff retention, CDER director Patrizia Cavazzoni says attrition rates are back to historical levels.
US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade
HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.